EBV Env Specific Neutra™ Antibody Products

Struggling with challenges in EBV therapeutic development, such as prolonged timelines or inconsistent antibody specificity? Creative Biolabs' EBV Env specific Neutra™ antibody products leverage advanced epitope mapping and hybridoma engineering to deliver high-affinity antibodies, accelerating antiviral drug discovery and enabling robust functional assays.

Introduction to EBV Env

The Epstein-Barr virus envelope protein (EBV Env), essential for viral entry, comprises glycoproteins gp350 and gp42. These mediate host cell attachment via CD21 and HLA class II receptors, respectively. EBV Env is critical during early infection, facilitating viral entry into B cells and epithelial cells, and is conserved across EBV strains. Its expression peaks during lytic replication, making it a pivotal target for neutralizing antibodies and therapeutic intervention.

Fig.1 Schematic of B-cell infection by EBV.¹

• Structural Insights

EBV Env exists as a heterodimer stabilized by disulfide bonds. The gp350 subunit binds CD21 with high avidity, initiating viral adsorption, while gp42 interacts with HLA class II to trigger membrane fusion. Structural studies reveal that gp350 adopts a rigid, repetitive architecture, whereas gp42 undergoes conformational changes during fusion. Glycosylation sites on gp350 shield immunogenic epitopes, posing challenges for antibody development, yet conserved regions within gp42 offer actionable targets for neutralization.

• Associated Signaling Pathways

EBV Env engagement activates NF-κB and MAPK pathways, driving host cell proliferation and immune evasion. Viral glycoproteins also modulate IFN-α/β signaling, suppressing innate antiviral responses. These pathways contribute to viral persistence and oncogenesis, underscoring the importance of neutralizing EBV Env to disrupt both acute infection and latent transformation.

• Disease Relevance

EBV is linked to infectious mononucleosis, nasopharyngeal carcinoma, and lymphoproliferative disorders. Its envelope proteins directly enable viral spread and immune evasion, perpetuating chronic infections and oncogenic microenvironments. Targeting EBV Env is thus vital for mitigating EBV-associated pathologies and developing therapies for immunocompromised patients.

Applications of Anti-EBV Env Neutralizing Antibodies

• Therapeutic Development for EBV-Associated Cancers

Neutralizing antibodies against EBV Env are pivotal in blocking viral entry into epithelial cells, a critical step in nasopharyngeal carcinoma progression. By disrupting gp350-CD21 binding, these antibodies reduce viral load and inhibit oncogenic signaling in preclinical models.

• Diagnostic Tools for Active Infection Monitoring

High-affinity anti-EBV Env antibodies enable sensitive detection of viral particles in patient sera or biopsies. ELISA-based platforms using these antibodies provide rapid, quantitative assessments of viral replication, aiding in early diagnosis and treatment monitoring.

• Vaccine Efficacy Evaluation

EBV Env-neutralizing antibodies serve as biomarkers to measure vaccine-induced immune responses. In clinical trials, antibody titers correlate with protection against primary EBV infection, guiding the optimization of glycoprotein-based vaccine candidates.

• Passive Immunotherapy for High-Risk Populations

Prophylactic administration of neutralizing antibodies protects immunocompromised patients, such as organ transplant recipients, from EBV reactivation. This approach reduces post-transplant lymphoproliferative disorder risks, offering immediate immunity where vaccines are impractical.

Our Anti-EBV Env Antibodies

Creative Biolabs' EBV Env-specific antibodies are engineered for high specificity and neutralizing potency. These antibodies target two key domains:

- gp350-binding antibodies: Block CD21 interaction, preventing viral attachment.

- gp42-neutralizing antibodies: Inhibit membrane fusion by binding to the HLA class II interaction domain.

Validated in functional assays, these antibodies exhibit cross-strain reactivity and minimal off-target effects. Applications include flow cytometry for viral load quantification, immunohistochemistry for tissue-specific EBV detection, and live-cell neutralization assays to evaluate therapeutic candidates.

Creative Biolabs provides EBV Env specific Neutra™ antibody products, empowering researchers to overcome challenges in antiviral drug development and diagnostics. With rigorously validated specificity and scalable production, our antibodies are tailored for precision in preclinical and clinical studies.

Contact our team today to explore custom solutions for your EBV research or therapeutic programs.

REFERENCE

1. Ross, Aisling M., et al. "Epstein–Barr virus and the pathogenesis of diffuse large B-Cell lymphoma." Life 13.2 (2023): 521. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/life13020521